{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056852","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.398709+00:00","generated_at":"2026-06-02T05:23:10.858617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics Q1 revenue $1.9M; $391M cash; advances FT819 in SLE, halts FT576 expansion","bullets":["Cash, equivalents & investments: $391.1M as of March 31, 2024, including ~$80M offering and ~$20M private placement.","Q1 revenue $1.9M (collaboration with Ono); GAAP operating expenses $53.0M (R&D $32.1M, G&A $20.9M, incl $11M stock comp).","First SLE patient treated with FT819 CAR T; dose escalation completed in BCM; FT819 development to focus exclusively on autoimmunity.","FT522 enrollment opened without conditioning chemotherapy in Phase 1 BCL; IND for autoimmunity planned mid-2024.","FT576 dose escalation completed in multiple myeloma; company will not advance to Phase 1 dose expansion; evaluating next-gen BCMA candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056852","json":"https://secwatch.observer/filing/0000950170-24-056852.json","markdown":"https://secwatch.observer/filing/0000950170-24-056852.md","text":"https://secwatch.observer/filing/0000950170-24-056852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/0000950170-24-056852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/fate-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:23:10.858617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc4fed12849df42b11ac49a4a728dff7a223a03e","claim":"FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/0000950170-24-056852-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}